The study explores the acceptability of ‘as needed’ biologic therapy for psoriasis among patients and clinicians, revealing that 67% of patients and 78% of clinicians support this approach. Both groups recognize its potential to reduce treatment burden and enhance patient ownership of care, while also identifying challenges related to medication logistics and disease management. The findings suggest a need for further assessment of the clinical effectiveness and cost-effectiveness of this treatment strategy.

The research discusses the development of new oral and topical small-molecule treatments for moderate-to-severe psoriasis, highlighting the approval of deucravacitinib, an oral Tyk2 inhibitor, and topical agents like tapinarof and roflumilast. It emphasizes the ongoing efforts to improve the efficacy and safety of these therapies in light of recent advances in understanding psoriasis pathogenesis.

This observational study analyzed treatment regimens and effectiveness for psoriasis among 407 patients in Southeast China, revealing that first-time diagnosed patients had a higher treatment response rate compared to those previously treated. The findings indicate lower response rates in real-world settings compared to clinical trials, highlighting unmet needs in psoriasis management and suggesting that combination and rotational strategies may enhance outcomes for unresponsive patients.

This systematic review examines the various methotrexate dosing regimens for treating atopic dermatitis, highlighting the lack of consensus and the risks of underdosing or overdosing. It summarizes findings from five randomized controlled trials and 21 guidelines, noting that while dosing varies, all studies showed efficacy in improving symptoms. The review serves as a resource for clinicians and aims to inform future consensus on dosing guideline

Abrocitinib demonstrated significant efficacy in improving skin clearance and reducing itch in patients with moderate-to-severe atopic dermatitis over a long-term period of up to 48 weeks, with approximately 52% achieving clear or almost clear skin and 82% showing substantial improvement in eczema severity. The safety profile was manageable, with common treatment-emergent adverse events including nasopharyngitis and nausea.